In late breaking clinical trials presented today at the American Heart Association Scientific Sessions, results of the ROCKET AF trial indicated that in an atrial fibrillation patient population that was at a very high risk of stroke, rivaroxaban (Xarelto) was as good as warfarin at preventing strokes.
Learn more at: Rivaroxaban comparable to warfarin in preventing stroke and other complications of irregular heartbeat
Add a CommentComments
There are no comments yet. Be the first one and get the conversation started!